Search

Lysosomal degradation of the endoplasmic reticulum (ER) via autophagy (ER‐phagy) is emerging as a critical regulator of cell homeostasis and function. The recent identification of ER‐phagy receptors has shed light on the molecular mechanisms underlining this process. However, the signaling pathways regulating ER‐phagy in response to cellular needs are still largely unknown. We found that the nutrient responsive transcription factors TFEB and TFE3—master regulators of lysosomal biogenesis and autophagy—control ER‐phagy by inducing the expression of the ER‐phagy receptor FAM134B. The TFEB/TFE3‐FAM134B axis promotes ER‐phagy activation upon prolonged starvation. In addition, this pathway is activated in chondrocytes by FGF signaling, a critical regulator of skeletal growth. FGF signaling induces JNK‐dependent proteasomal degradation of the insulin receptor substrate 1 (IRS1), which in turn inhibits the PI3K‐PKB/Akt‐mTORC1 pathway and promotes TFEB/TFE3 nuclear translocation and enhances FAM134B transcription. Notably, FAM134B is required for protein secretion in chondrocytes, and cartilage growth and bone mineralization in medaka fish. This study identifies a new signaling pathway that allows ER‐phagy to respond to both metabolic and developmental cues. Synopsis: The signalling pathways inducing autophagic degradation of the endoplasmic reticulum (ER‐phagy) to regulate cellular homeostasis are ill‐defined. Here, ER‐phagy in chondrocytes promoting bone development is found to be regulated by fibroblast growth factor 18 (FGF18), which induces nuclear translocation of TFEB/TFE3 transcription factors and expression of FAM134B. MiTF/TFE transcription factors promote expression of FAM134B and ER‐phagy in mammalian cells.Prolonged starvation leads to the activation of the TFEB/TFE3‐FAM134B axis and ER‐phagy.In chondrocytes, FGF18 induces ER‐phagy through JNK‐mediated degradation of the IRS1 protein.FAM134B is required for protein secretion in chondrocytes, and for cartilage growth and bone mineralization in medaka fish. [ABSTRACT FROM AUTHOR]

Abstract: Currently there is no direct therapy for liver failure. We have previously described selective plasma exchange therapy using a hemofilter permeable to substances that have a molecular mass of up to 100 kDa. The proof‐of‐concept studies and a Phase I study in patients with decompensated cirrhosis demonstrated that hemofiltration using an albumin‐leaking membrane is safe and effective in removing target molecules, alleviating severe encephalopathy and improving blood chemistry. In this study a novel large‐pore filter for similar clinical application is described. The performance of the filter was studied in vitro; it was found to effectively remove a wide spectrum of pathogenic factors implicated in the pathophysiology of hepatic failure, including protein bound toxins and defective forms of circulating albumin. Data on mass transport characteristics and functionality using various modes of filtration and dialysis provide rationale for clinical evaluation of the filter for artificial liver support using albumin apheresis. [ABSTRACT FROM AUTHOR]

Abstract: Technical problems during clinical lipid apheresis interfere with fractionator performance. Therefore, a large animal model was established to characterize a new plasma fractionation membrane. Four sheep were randomized, controlled, and crossover subjected to double ofiltration lipoprotein apheresis with three specimens of FractioPESR having slightly different HDL sieving coefficients (SK) (FPESa, 0.30, FPESb, 0.26, and FPESc, 0.22) versus a control fractionator (EVAL). SK and reduction ratios were determined for LDL, HDL, fibrinogen, IgG, and albumin. Compared to EVAL (0.42 ± 0.04 to 0.74 ± 0.08) and FPESa (0.36 ± 0.06 to 0.64 ± 0.04), SK for HDL were lower (P < 0.05) with FPESc (0.30 ± 0.04 to 0.49 ± 0.10). Fibrinogen SK were higher (P < 0.05) with EVAL (0.02 ± 0.01 to 0.40 ± 0.08) compared to FPESb (0.05 ± 0.02 to 0.26 ± 0.34) and FPESc (0.01 ± 0.01 to 0.21 ± 0.16). No further differences were determined. The animal model distinguished between minor differences in fractionation membrane permeability, demonstrating equivalent sieving of FPESa and EVAL and slightly inferior permeability of FPESb and FPESc. [ABSTRACT FROM AUTHOR]

m-AAA proteases exert dual functions in the mitochondrial inner membrane: they mediate the processing of specific regulatory proteins and ensure protein quality control degrading misfolded polypeptides to peptides. Loss of these activities leads to neuronal cell death in several neurodegenerative disorders. However, it is unclear how the m-AAA protease chooses between specific processing and complete degradation. A central and conserved function of the m-AAA protease is the processing of the ribosomal subunit MrpL32, which regulates ribosome biogenesis and the formation of respiratory complexes. Here, we demonstrate that the formation of a tightly folded domain harbouring a conserved CxxC-X9-CxxC sequence motif halts degradation initiated from the N-terminus and triggers the release of mature MrpL32. Oxidative stress impairs folding of MrpL32, resulting in its degradation by the m-AAA protease and decreased mitochondrial translation. Surprisingly, MrpL32 folding depends on its mitochondrial targeting sequence. Presequence-assisted folding of MrpL32 requires the complete import of the MrpL32 precursor before maturation occurs and therefore explains the need for post-translocational processing by the m-AAA protease rather than co-translocational cleavage by the general mitochondrial processing peptidase. [ABSTRACT FROM AUTHOR]

An autosomal recessive form of hereditary spastic paraplegia (AR-HSP) is primarily caused by mutations in the SPG7 gene, which codes for paraplegin, a subunit of the hetero-oligomeric m-AAA protease in mitochondria. In the current study, sequencing of the SPG7 gene in the genomic DNA of 25 unrelated HSP individuals/families led to the identification of two HSP patients with compound heterozygous mutations (p.G349S/p.W583C and p.A510V/p.N739KfsX741) in the coding sequence of the SPG7 gene. We used a yeast complementation assay to evaluate the functional consequence of novel SPG7 sequence variants detected in the HSP patients. We assessed the proteolytic activity of hetero-oligomeric m-AAA proteases composed of paraplegin variant(s) and proteolytically inactive forms of AFG3L2 (AFG3L2E575Q or AFG3L2K354A) upon expression in m-AAA protease-deficient yeast cells. We demonstrate that the newly identified paraplegin variants perturb the proteolytic function of hetero-oligomeric m-AAA protease. Moreover, commonly occurring silent polymorphisms such as p.T503A and p.R688Q could be distinguished from mutations (p.G349S, p.W583C, p.A510V, and p.N739KfsX741) in our HSP cohort. The yeast complementation assay thus can serve as a reliable system to distinguish a pathogenic mutation from a silent polymorphism for any novel SPG7 sequence variant, which will facilitate the interpretation of genetic data for SPG7. Hum Mutat 31:1-5, 2010. © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]

Autophagy is a highly conserved catabolic process through which defective or otherwise harmful cellular components are targeted for degradation via the lysosomal route. Regulatory pathways, involving post‐translational modifications such as phosphorylation, play a critical role in controlling this tightly orchestrated process. Here, we demonstrate that TBK1 regulates autophagy by phosphorylating autophagy modifiers LC3C and GABARAP‐L2 on surface‐exposed serine residues (LC3C S93 and S96; GABARAP‐L2 S87 and S88). This phosphorylation event impedes their binding to the processing enzyme ATG4 by destabilizing the complex. Phosphorylated LC3C/GABARAP‐L2 cannot be removed from liposomes by ATG4 and are thus protected from ATG4‐mediated premature removal from nascent autophagosomes. This ensures a steady coat of lipidated LC3C/GABARAP‐L2 throughout the early steps in autophagosome formation and aids in maintaining a unidirectional flow of the autophagosome to the lysosome. Taken together, we present a new regulatory mechanism of autophagy, which influences the conjugation and de‐conjugation of LC3C and GABARAP‐L2 to autophagosomes by TBK1‐mediated phosphorylation. Synopsis: LC3C and GABARAP‐L2 processing by ATG4 is controlled by TBK1‐mediated phosphorylation. This regulatory mechanism prevents premature shedding of LC3C and GABARAP‐L2 from autophagosomes. TBK1 phosphorylates autophagy modifiers LC3C and GABARAP‐L2 on surface‐exposed serine‐residues.GABARAP‐L2 S87/88‐PO4 and LC3C S93/96‐PO4 impedes binding to the ATG4 protease.Phosphorylated LC3C/GABARAP‐L2 are protected from ATG4‐mediated premature removal from autophagosomes. [ABSTRACT FROM AUTHOR]